NeuroSense Therapeutics Ltd. secures Nasdaq hearing
- Nasdaq hearing scheduled for November 10, 2026
- New Drug Submission to Health Canada targeted for December 2026
- Non-dilutive funding decision for Phase 3 PARAGON expected in Q1 2027
Every EDGAR filing for NeuroSense Therapeutics Ltd. (NRSNW), newest first, with AI summaries and stories.
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Or Eisenberg, insider filing for NRSNW
Or Eisenberg, reporting
Or Eisenberg, insider filing for NRSNW
Or Eisenberg, reporting
Revital Mandil-Levin, new insider at NRSNW
Revital Mandil-Levin, reporting
Niva Russek-Blum, insider filing for NRSNW
Niva Russek-Blum, reporting
Alon Ben-Noon, new insider at NRSNW
Alon Ben-Noon, reporting
Christine A Pellizzari, new insider at NRSNW
Christine A Pellizzari, reporting